Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
8.67
Dollar change
+0.09
Percentage change
1.05
%
Index- P/E- EPS (ttm)-0.90 Insider Own19.29% Shs Outstand132.23M Perf Week6.25%
Market Cap1.15B Forward P/E189.22 EPS next Y0.05 Insider Trans0.00% Shs Float106.79M Perf Month8.10%
Income-119.03M PEG- EPS next Q-0.03 Inst Own86.17% Short Float6.88% Perf Quarter30.18%
Sales288.94M P/S3.97 EPS this Y-154.23% Inst Trans-0.48% Short Ratio2.73 Perf Half Y-11.17%
Book/sh3.15 P/B2.75 EPS next Y381.65% ROA-6.31% Short Interest7.35M Perf Year-36.72%
Cash/sh4.35 P/C2.00 EPS next 5Y- ROE-24.75% 52W Range4.52 - 16.62 Perf YTD32.37%
Dividend Est.- P/FCF18.91 EPS past 5Y-37.53% ROI-11.73% 52W High-47.83% Beta0.00
Dividend TTM- Quick Ratio7.41 Sales past 5Y57.89% Gross Margin47.59% 52W Low91.81% ATR (14)0.52
Dividend Ex-Date- Current Ratio8.00 EPS Y/Y TTM-153.82% Oper. Margin-2.50% RSI (14)64.87 Volatility5.91% 6.74%
Employees650 Debt/Eq1.47 Sales Y/Y TTM-67.28% Profit Margin-41.19% Recom1.58 Target Price9.16
Option/ShortYes / Yes LT Debt/Eq1.44 EPS Q/Q-386.39% Payout0.00% Rel Volume0.86 Prev Close8.58
Sales Surprise15.17% EPS Surprise186.96% Sales Q/Q-63.78% EarningsFeb 22 AMC Avg Volume2.69M Price8.67
SMA2010.39% SMA5028.16% SMA2002.71% Trades Volume2,303,779 Change1.05%
Date Action Analyst Rating Change Price Target Change
Dec-12-23Upgrade BofA Securities Neutral → Buy $10 → $8
Aug-08-23Downgrade KeyBanc Capital Markets Overweight → Sector Weight
May-23-23Downgrade Credit Suisse Outperform → Neutral $18 → $14
May-09-23Downgrade Goldman Buy → Neutral
Jan-05-23Downgrade UBS Buy → Neutral $20 → $16
Dec-14-22Initiated Deutsche Bank Buy $25
Dec-07-22Initiated RBC Capital Mkts Outperform $22
Nov-03-22Downgrade BofA Securities Buy → Neutral $32 → $17
Aug-25-22Initiated Credit Suisse Outperform $34
Aug-05-21Resumed Credit Suisse Outperform $44
Today 04:00PM
Mar-19-24 07:48AM
Mar-12-24 04:15PM
Feb-23-24 12:15PM
10:10AM
08:30PM Loading…
Feb-22-24 08:30PM
04:43PM
04:05PM
Feb-21-24 08:00AM
Feb-13-24 08:30AM
Feb-11-24 05:00PM
Feb-07-24 06:46AM
Jan-29-24 08:00AM
Dec-18-23 05:27AM
Nov-24-23 08:39AM
08:15AM Loading…
Nov-09-23 08:15AM
Nov-08-23 04:02PM
12:00AM
Nov-07-23 04:49PM
04:05PM
Nov-02-23 06:47AM
Oct-20-23 12:08PM
Oct-17-23 08:15AM
Sep-29-23 12:43PM
08:15AM
Sep-25-23 08:49AM
Sep-19-23 09:31AM
Sep-05-23 04:15PM
Aug-23-23 08:15AM
Aug-22-23 08:14AM
04:15PM Loading…
Aug-09-23 04:15PM
06:03AM
Aug-08-23 06:20AM
01:30AM
Aug-07-23 04:05PM
Jul-27-23 04:05PM
Jul-24-23 04:05PM
Jul-20-23 04:05PM
Jul-18-23 08:37AM
Jul-16-23 08:51AM
Jun-06-23 08:00AM
May-24-23 08:10AM
May-09-23 12:49PM
08:00AM
01:00AM
May-08-23 05:35PM
04:05PM
Apr-17-23 04:15PM
Mar-28-23 05:00PM
Mar-20-23 06:50AM
Mar-13-23 08:45AM
Mar-09-23 06:40AM
Mar-08-23 08:00AM
Mar-04-23 08:19AM
Mar-02-23 08:45AM
Feb-27-23 05:35AM
Feb-23-23 01:00AM
Feb-22-23 05:55PM
04:05PM
Feb-16-23 10:01AM
Feb-15-23 10:00AM
Feb-14-23 04:33PM
Feb-07-23 10:15AM
Feb-06-23 07:34AM
Feb-01-23 08:00AM
Jan-27-23 09:37AM
Jan-16-23 08:30AM
Dec-12-22 09:53AM
Dec-01-22 04:01PM
Nov-28-22 08:30AM
Nov-16-22 05:05PM
Nov-09-22 07:16AM
Nov-07-22 04:10PM
Nov-06-22 07:30AM
Nov-03-22 04:05PM
12:30AM
Nov-02-22 06:15PM
04:05PM
Oct-29-22 08:45AM
Oct-24-22 10:39AM
Oct-19-22 08:10AM
Oct-18-22 04:15PM
Oct-13-22 08:32PM
Oct-08-22 08:28AM
Oct-06-22 11:28AM
Oct-03-22 04:05PM
Sep-13-22 08:00AM
Aug-29-22 01:47PM
Aug-17-22 08:42AM
Aug-15-22 04:05PM
Aug-05-22 01:30PM
10:30AM
Aug-04-22 05:55PM
04:51PM
04:03PM
Aug-02-22 10:00AM
Jul-28-22 10:03AM
Jul-23-22 05:58AM
Jul-22-22 05:49AM
Jul-21-22 02:13PM
Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers' research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.